Catalyst to Acquire Commercial Rights of Eisai’s Fycompa (perampanel) CIII in the US
Shots:
- Eisai will receive $160M up front & is also eligible to receive milestones along with royalties. The transaction is expected to close early in Q1’23 & Fycompa is expected to have patent protection through May 2025 with a possible extension into 2026
- Catalyst gets an exclusive option period to evaluate & negotiate the acquisition of a rare epilepsy compound in Eisai's pipeline. Eisai will maintain its rights to Fycompa outside the US and will manufacture & supply to global markets incl. the US
- The acquisition expands Catalyst’s commercial portfolio with the US-marketed product in neurology and enhances the growth potential of Fycompa. Catalyst also gets an exclusive option to add a late-stage rare neurology asset for rare neurological & epileptic disorders
Ref: Eisai | Image: Eisai
Related News:- Eisai's Fycompa (perampanel) Receives EC's Approval for Expanded Indication in Pediatric Patients with POS and PGTCS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
